Drugs Made In America Acquisition Corp. (DMAA) stock
DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)
Close on Nov 17, 2026Market cap $264.62MP/E –Yield –
Drugs Made In America Acquisition operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Drugs Made In America Acquisition's operating cash flow for the twelve months ending Jun 30, 2026 was -$517.15K. For fiscal 2025 it was -$539.19K.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$539.19K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$244.61K | – |
| Q1 FY2026 | Mar 31, 2026 | -$91.25K | – |
| Q4 FY2025 | Dec 31, 2025 | -$125.18K | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.11K | – |
| Q2 FY2025 | Jun 30, 2025 | -$106.66K | – |
| Q1 FY2025 | Mar 31, 2025 | -$251.24K | – |
See a number that looks wrong?